The Cooper Companies (COO) Earnings: Q3 Fiscal 2026 Results and Next Report Date

The quarter ended July 31, 2026 and CooperCompanies published the results on September 9, 2026. Revenue and diluted EPS are shown against Q3 fiscal 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. CooperCompanies reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• CooperCompanies' fiscal year ends October 31, so Q3 fiscal 2026 covers May through July 2026.
• GAAP net income and EPS include a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination (HMRC) of the fiscal 2021 transfer of CooperVision intellectual property to the United Kingdom. Non-GAAP EPS excludes it.

Source: CooperCompanies Q3 fiscal 2026 results, September 9, 2026. Also in the Form 10-Q for the quarter ended July 31, 2026. Figures as reported; checked against the release on November 10, 2026.

How CooperCompanies splits revenue in its own release, under its own labels, for Q3 fiscal 2026 against Q3 fiscal 2025. Indented lines are parts of the line above them.

• CooperCompanies's CooperVision revenue was $717 million in Q3 fiscal 2026, flat on $718 million in Q3 fiscal 2025, 67% of total revenue.
• CooperCompanies's CooperSurgical revenue was $349 million in Q3 fiscal 2026, up 2% from $342 million in Q3 fiscal 2025, 33% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 fiscal 2026 release, CooperCompanies said:

“Fiscal fourth quarter 2026 total revenue of $1.057-$1.080 billion (organic growth of 0% to 2%)”

“Fiscal fourth quarter 2026 non-GAAP diluted EPS of $1.05-$1.09”

“Fiscal 2026 total revenue of $4.229-$4.252 billion (organic growth of 2% to 3%)”

“Fiscal 2026 non-GAAP diluted EPS of $4.51-$4.55”

Source: CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026.

This is the company's own guidance as of Sep 9, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the COO forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release. The Q2 fiscal 2026 loss of $0.40 per share came from a litigation-related charge tied to a December 2023 product recall at CooperSurgical.

CooperCompanies's next report is scheduled for December 3, 2026. This page will show Q3 fiscal 2026 until those results are out and have been checked against the release.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 fiscal 2026 (this page), reported Sep 9, 2026

CooperCompanies has two businesses. CooperVision, which makes single-use, two-week and monthly contact lenses, had net sales of $717.0 million in Q3 fiscal 2026, against $718.4 million a year earlier. CooperSurgical, which sells fertility and women's health care products and services, had $349.2 million against $341.9 million. Total revenue rose 1% to $1,066.2 million, and 1% organically. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026; CooperCompanies Form 10-Q, Q3 fiscal 2026, Sep 9, 2026; CooperCompanies Form 10-K, fiscal 2025, Dec 5, 2025)

CooperVision was flat because CooperCompanies reduced U.S. channel inventory. Americas sales fell 2% to $281.6 million, which the 10-Q puts down to those reductions, and Asia Pacific fell 10% to $126.0 million on softness in Japan and China. EMEA rose 6% to $309.4 million on market gains of silicone hydrogel lenses and favorable exchange rates. The CEO said the inventory reduction will continue to affect Q4. (CooperCompanies Form 10-Q, Q3 fiscal 2026, Sep 9, 2026; CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

By lens type, CooperVision's toric and multifocal lenses, which correct astigmatism and presbyopia, brought in $363.8 million, up 1%, and sphere and other lenses $353.2 million, down 2%. The 10-Q names Biofinity and MyDay as the growth drivers for toric and multifocal over the nine months, and MiSight and MyDay for sphere. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026; CooperCompanies Form 10-Q, Q3 fiscal 2026, Sep 9, 2026)

Within CooperSurgical, fertility sales rose 3% to $141.2 million (5% organically) and office and surgical sales rose 2% to $208.0 million. Fertility covers products and services for in vitro fertilization, including consumables, donor gamete services and genetic testing; office and surgical includes medical devices, cord blood and tissue storage, and contraception. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026; CooperCompanies Form 10-Q, Q3 fiscal 2026, Sep 9, 2026)

On the same day as the results, CooperCompanies said its strategic review was complete and the Board had decided to keep CooperSurgical after evaluating a sale, because the offers received were not in shareholders' best interest. It expanded the share repurchase authorization from $2 billion to $3 billion. (CooperCompanies strategic review release (Exhibit 99.2), Sep 9, 2026; CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

CooperCompanies' GAAP diluted EPS of $2.24 was almost double its non-GAAP EPS of $1.15 in Q3 fiscal 2026, because GAAP results include a $307.2 million discrete tax benefit from the favorable completion of an HMRC examination of the fiscal 2021 transfer of CooperVision's intellectual property to the U.K. The effective tax rate for the quarter was (114.5)% against 35.3% a year earlier. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026; CooperCompanies Form 10-Q, Q3 fiscal 2026, Sep 9, 2026)

Non-GAAP EPS also excludes amortization of acquired intangibles ($47.0 million, or $0.24 per share), costs of complying with E.U. medical device regulations, business optimization charges and other items such as litigation and strategic review costs. Non-GAAP EPS rose 4% from $1.10. GAAP operating margin was 21% against 17%, and non-GAAP operating margin rose 30 basis points to 26%. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

CooperCompanies repurchased about 4.9 million shares for $339.1 million in the quarter at an average price of $69.16, and weighted average diluted shares fell to 193.4 million from 200.0 million. About $1.5 billion remains under the expanded program. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

CooperCompanies gives a quarterly and full-year outlook in its release. For Q4 fiscal 2026 it guided total revenue of $1.057 billion to $1.080 billion (organic growth of 0% to 2%), with CooperVision at $692 million to $706 million and CooperSurgical at $364 million to $374 million, and non-GAAP diluted EPS of $1.05 to $1.09. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

For the full fiscal year 2026 the guidance is total revenue of $4.229 billion to $4.252 billion and non-GAAP diluted EPS of $4.51 to $4.55. CooperCompanies does not reconcile its EPS guidance to GAAP, and it reaffirmed a free cash flow objective of more than $2.2 billion over fiscal years 2026 through 2028. (CooperCompanies Q3 fiscal 2026 release, Sep 9, 2026)

A consensus figure is the average of the models published by the analysts who cover CooperCompanies, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones CooperCompanies's own release and filings put weight on for Q3 fiscal 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning COO is on is COO a buy or a sell?, what analysts expect next is on the COO forecast, and what the company does is on the The Cooper Companies (COO) stock page.

Every number on this page can be traced to a document CooperCompanies published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.